Laparoendoscopic single-site surgery for the assessment of peritoneal carcinomatosis resectability in patients with advanced ovarian cancer

Purpose of investigation: To evaluate the feasibility, safety, and effectiveness of laparoendoscopic single site surgery (LESS) for the assessment of peritoneal carcinomatosis resectability in patients with advanced stage ovarian cancer (AOC). Materials and Methods: The authors retrospectively reviewed the medical records of patients affected by advanced stage ovarian cancer who underwent LESS for operative work-up. A standard cytoreductive laparotomy surgery (CRS) was performed. Results: Fifty-two women affected by AOC underwent LESS for operative work-up. The peritoneal cancer score was completed in 49 (94%) patients by use of LESS; 34/37 (92%) patients considered with a resectable disease were effectively optimally debulked and 15/52 (28%) patients considered with an unresectable disease received before neoadjuvant chemotherapy (NACT) and then underwent surgery. Conclusion: LESS is feasible, safe, and is an alternative minimally invasive procedure to assess the resectability of AOC patients.

Laparoendoscopic single-site surgery (LESS); Single-port laparoscopy; Advanced epithelial ovarian cancer; Peritoneal carcinomatosis; Residual tumor.

[1] Griffiths C.T.: “Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma”. Natl. Cancer Inst. Monogr., 1975, 42, 101.

[2] Chi D.S., Liao J.B., Leon L.F., Venkatraman E.S., Hensley M.L., Bhaskaran D., Hoskins W.J.: “Identification of prognostic factors in advanced epithelial ovarian carcinoma”. Gynecol. Oncol., 2001, 82, 532.

[3] Chéreau E., Ballester M., Selle F., Cortez A., Daraï E., Rouzier R.: “Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer”. Am. J. Obstet. Gynecol., 2010, 202, 178.e1.

[4] Nezhat F.R., DeNoble S.M., Liu C.S., Cho J.E., Brown D.N., Chuang L., et al.: “The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers”. JSLS, 2010, 14, 155.

[5] Fader A.N., Escobar P.F.: “Laparoendoscopic single-site surgery (LESS) in gynecologic oncology: technique and initial report”. Gynecol. Oncol., 2009, 114, 157.

[6] Fagotti A., Ferrandina G., Fanfani F., Ercoli A., Lorusso D., Rossi M., Scambia G.: “A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study”. Ann. Surg. Oncol., 2006, 13, 1156.

[7] Vergote I., De Wever I., Tjalma W., Gramberen M., Van Decloedt J., Van Dam P.: “Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients”. Gynecol. Oncol., 1998, 71, 431.

[8] Bradford L.S., Boruta D.M.: “Laparoendoscopic single-site surgery in gynecology: a review of the literature, tools, and techniques”. Obstet. Gynecol. Surv., 2013, 68, 295.

[9] Varnoux C., Huchon C., Bats A.S., Bensaid C., Achouri A., Nos C., Lécuru F.: “Diagnostic accuracy of hand-assisted laparoscopy in predicting resectability of peritoneal carcinomatosis from gynecological malignancies”. Eur. J. Surg. Oncol., 2013, 39, 774.

[10] Stoeckle E., Bourdarias L., Guyon F., Croce S., Brouste V., Thomas L., Floquet A.: “Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxanebased chemotherapy and late interval debulking surgery”. Ann. Surg. Oncol., 2014, 21, 629.

[11] Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M.J..: “Cancer statistics, 2006”. CA Cancer J Clin., 2006, 56, 106.

[12] Benedet J.L., Bender H., Jones H. 3rd, Ngan H.Y., Pecorelli S.: “FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology”. Int. J. Gynaecol. Obstet., 2000, 70, 209.